TIDMVLG
RNS Number : 3760H
Venture Life Group PLC
15 November 2018
VENTURE LIFE GROUP PLC
("Venture Life" or the "Group")
Commercial Update
First long term international distribution agreements signed for
recently acquired Dentyl(Ò) brand, and continued international
expansion of UltraDEX and other brands
Venture Life Group plc (AIM: VLG), the international consumer
healthcare group focused on developing, manufacturing and
commercialising products for the self-care market, announces its
first long-term international distribution agreements signed for
the recently acquired Dentyl(Ò) brand, together with other
commercial progress.
Dentyl(Ò)
Venture Life announces its first 10 year distribution deal in
Ireland with Eurosales International Ltd ("Eurosales") for the
recently acquired Dentyl brand. Eurosales is a leading retail
distribution company operating in Ireland which distributes brands
such as Palmer's Cocoa Butter Formula and P20. Eurosales will
launch the Dentyl brand in Q1 2019 into new grocery and pharmacy
channels both in Republic of Ireland and Northern Ireland.
Currently Dentyl is only available in Ireland through Tesco
stores.
Dentyl has also been partnered with Collis William in Malta.
Founded in 1860, the company distributes its products to both
pharmacies and the mass market retailers.
The Group also announces that the first UK outdoor digital
display advertising campaign for Dentyl since the acquisition will
take place in November 2018 and will be shown for three weeks in
five key UK cities - London, Manchester, Birmingham, Liverpool and
Leeds, with an estimated reach of 1.5millon people. This will be
the brand's first advertising campaign since 2015.
In addition, Amazon and Ocado will launch both Dentyl
mouthwashes and BB Mints in the UK in November and December 2018,
respectively. These online retailers have been important partners
for UltraDEX in the UK and we expect this to be same for the Dentyl
range moving forward.
UltraDEX(TM) - success continues
The success of UltraDEX internationally also continues with the
recent partnering in three new markets - China, Ireland and Malta.
Venture Life's partner in Ireland will be Eurosales and its partner
in Malta will be Metropolis Pharma Ltd. In China, the existing
partner for Dentyl will launch UltraDEX in Q4 2018 across mainland
China, via the online channel. In addition to this, UltraDEX has
received registration approval in Dubai, and the launch will take
place in Q1 2019 with its distribution partner Delta Medical.
UltraDEX is now partnered in 18 markets in total.
In the UK, Tesco has increased the distribution of UltraDEX
Low-Abrasion Toothpaste from 234 to 403 stores, an increase of 72%,
which has resulted in the highest level of sales of UltraDEX
toothpaste in Tesco since the start of 2015.
International market expansion
Following successful registration, Venture Life also announces
the launch of Immobilice[1], vonalei[2] and Procto-eze Plus[3] in
Israel, and it has a new partner for NeuroAge[4] in Greece. This
product was originally partnered in Greece in 2012 with Elpen
Pharmaceuticals. In recent years, Elpen has failed to perform in
accordance with its obligations under our agreement, so the Group
has exercised its contractual right to terminate the agreement and
appoint a replacement partner, Bennett Pharmaceutical Industry
("Bennett"). Bennett, the 2(nd) largest local Greek pharmaceutical
company, will adopt a different route-to-market strategy and will
launch NeuroAge in Q1 2019.
Jerry Randall, CEO of Venture Life, commented: "I am delighted
with the commercial progress of the company over the last few
months, in particular, with the recent international deals on the
Dentyl brand. In addition to this, the UltraDEX brand continues to
develop in our hands, both in the UK and internationally,
demonstrating the strength of our commercial platform to grow the
brand. A similar strategy will be applied to Dentyl and we expect
more success over the coming months and years. This recent success
is testament not only to the interesting products that we have
acquired into our portfolio, but to the extremely high level of
customer service and quality we deliver to our customers.
"The progress made so far in the second half of 2018
demonstrates the continued success of our 'buy and build' growth
strategy to acquire interesting, consumer self-care brands with
potential, that allows us to revitalise, innovate, manufacture and
internationalise these brands, to help grow revenues."
For further information, please contact:
+44 (0) 1344
Venture Life Group PLC 578004
Jerry Randall, Chief Executive Officer
Adrian Crockett, Chief Financial Officer
Northland Capital Partners Limited (Nominated +44 (0) 20 3861
Adviser and Joint Broker) 6625
Matthew Johnson / Edward Hutton (Corporate Finance)
Vadim Alexandre (Corporate Broking)
+44 (0) 20 3861
Cenkos Securities Ltd (Joint Broker) 6630
Mark Connelly (Corporate Finance)
Russell Kerr / Michael Johnson (Sales)
Walbrook PR venturelife@walbrookpr.com or + 44
(0) 20 7933 8780
Anna Dunphy / Paul McManus +44 (0) 7876 741 001 / +44 (0)
7980 541 893
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the global self-care market. With operations in both the UK and
Italy, the Group's product portfolio includes some key products
such as the UltraDEX and Dentyl oral care product ranges, food
supplements for lowering cholesterol and maintaining brain
function, medical devices for women's intimate healthcare and
proctology and dermo-cosmetics for addressing the signs of
ageing.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies and grocery multiples. In the UK these are supplied
direct by the company, outside of the UK they are supplied by the
Group's international distribution partners.
Through its Development & Manufacturing business in Italy,
Biokosmes, the Group also provides development and manufacturing
services to companies in the medical devices and cosmetic
sectors.
[1] A pesticide-free head lice treatment
[2] A women's intimate healthcare range
[3] Indicated for anal irritation and haemorrhoids
[4] Indicated for mental performance in a healthy brain
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDBSBDBRUBBGIS
(END) Dow Jones Newswires
November 15, 2018 02:00 ET (07:00 GMT)
Venture Life (LSE:VLG)
Historical Stock Chart
From Apr 2024 to May 2024
Venture Life (LSE:VLG)
Historical Stock Chart
From May 2023 to May 2024